(Q38669328)

English

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

scientific article published on 17 July 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

0 references

multicenter clinical trial

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Alessandra Bearz

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Dariusz M Kowalski

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Paul K Stockman

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Martina Puglisi

16

object named as

Martina Puglisi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Michele Maio

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Arnaud Scherpereel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Joachim Aerts

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Susana Cedres Perez

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Kristiaan Nackaerts

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Dean A Fennell

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Anne S Tsao

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Paul Taylor

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Federica Grosso

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Scott J Antonia

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Maria Taboada

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Hedy L Kindler

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

17 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1261-1273

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune Checkpoint Blockade in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune checkpoint blockade in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A recycling framework for the construction of Bonferroni-based multiple tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Analyzing survival curves at a fixed point in time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of peritoneal malignant mesothelioma in Italy: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of toxicities of immune checkpoint inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy for malignant mesothelioma: Reality check

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930446-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30446-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729154%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38669328&oldid=2104627912"